Zabdeno (monovalent ebola virus vaccine) / J&J  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zabdeno (monovalent ebola virus vaccine) / J&J
NCT02416453 / 2015-000596-27: A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Completed
2
423
Europe
MVA-BN-Filo, Ad26.ZEBOV, Placebo
Janssen Vaccines & Prevention B.V., Institut National de la Santé Et de la Recherche Médicale, France, University of Oxford
Ebola Viral Disease
01/18
01/18
2017-004610-26: Evaluation the duration of the immune response of a late booster dose of a vaccine against Ebola virus disease - AD26.ZEBOV - in healthy adults previously immunised with investigational Ebola vaccine schedules.

Not yet recruiting
2
156
Europe
Ad26-ZEBOV, Suspension for injection
Clinical Trials and Research Governance (CTRG), University of Oxford, INNOVATE UK, Janssen UK
Ebola Virus Disease, Ebola virus disease (EVD), is a severe, often fatal disease in humans, spread by contact with body fluids., Diseases [C] - Virus Diseases [C02]
 
 
NCT02598388: Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Completed
2
578
US, RoW
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Janssen Vaccines & Prevention B.V., Walter Reed Army Institute of Research (WRAIR)
Hemorrhagic Fever, Ebola
12/18
12/18
NCT02564523 / 2019-000690-22: Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Completed
2
1075
RoW
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Janssen Vaccines & Prevention B.V., EBOVAC2 Consortium, Institut National de la Santé Et de la Recherche Médicale, France, Centre Muraz
Hemorrhagic Fever, Ebola
02/19
02/19
EBOVAC3DRC, NCT04186000: Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola

Completed
2
699
RoW
Ad26.ZEBOV vaccine
Universiteit Antwerpen, Johnson & Johnson, Ace Africa, Innovative Medicines Initiative, Coalition for Epidemic Preparedness Innovations, University of Kinshasa
Ebola Virus Disease
04/20
10/22
NCT04028349: ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

Completed
2
800
RoW
Ad26.ZEBOV/MVA-BN-Filo
MRC/UVRI and LSHTM Uganda Research Unit, Epicentre, Mbarara, Uganda, Janssen Pharmaceutica N.V., Belgium, Coalition for Epidemic Preparedness Innovations, Epicentre, Paris, France.
Ebola Virus Disease
03/21
03/21
NCT03929757 / 2021-001331-10: A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Completed
2
108
RoW
Ad26.ZEBOV, MVA-BN-Filo, MenACWY
Janssen Vaccines & Prevention B.V., London School of Hygiene and Tropical Medicine, College of Medicine and Allied Health Sciences (COMAHS), Institut National de la Santé Et de la Recherche Médicale, France
Ebola Virus Disease
08/22
09/22
NCT05284097: Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Active, not recruiting
2
133
RoW
Ad26.ZEBOV, MVA-BN-Filo, VAC52150
London School of Hygiene and Tropical Medicine, University of Sierra Leone, Janssen Vaccines & Prevention B.V.
Virus Diseases, Hemorrhagic Fever, Ebola, Infections, Hemorrhagic Fevers, Viral, RNA Virus Infections, Filoviridae Infections, Mononegavirales Infections, Vaccines, Immunologic Factors, Physiological Effects of Drugs, Ebola
12/23
05/24

Download Options